High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma

Journal of Clinical Pathology

Volumn 59, Issue 9, 2006, Pages 947-951

  Song, Y F ^a   Xu, R ^b   Zhang, X H ^c   Chen, B B ^a   Chen, Q ^a   Chen, Y M ^a   Xie, Y ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Center for Clinical Laboratory   (China)

^c Division of Internal Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; MESSENGER RNA; PROTEIN DLC1; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SEQUENCE; DRUG INHIBITION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METHYLATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AZACITIDINE; BASE SEQUENCE; BONE MARROW; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 33748861305     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.031377     Document Type: Article

References (28)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
2. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996;94:217-27.
3. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
4. Murai M, Toyota M, Satoh A, et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005;92:1165-72.
5. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687-92.
6. Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598-606.
7. Yuan BZ, Miller MJ, Keck CL, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196-9.
8. Ng IO, Liang ZD, Cao L, et al. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines wirh deleted DLC-1. Cancer Res 2000;60:6581-4.
9. Schmitz AA, Govek EE, Bottner B, et al. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 2000;261:1-12.
10. Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003;140:113-7.
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
12. Kim TY, Jong HS, Song SH, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 2003;22:3943-51.
13. Yuan BZ, Zhou X, Durkin ME, et al. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003;22:445-50.
14. Yaremko ML, Kutza C, Lyzak J, et al. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer 1990;16:189-95.
15. Park SW, Durkin ME, Thorgeirsson SS, et al. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma, Int J Oncol 2003;23:133-7.
16. Hewitt C, Wilson P, McGlinn E, et al. DLC1 is unlikely to be a primary target for deletions on chromosome arm 8p22 in head and neck squamous cell carcinoma. Cancer Lett 2004;209:207-13.
17. Yin XL, Pang JC, Ng HK. Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma. Oncogene 2002;21:1461-8.
18. Wilson PJ, McGlinn E, Marsh A, et al. Sequence variants of DLC1 in colorectal and ovarian tumours. Hum Mutat 2000;15:156-65.
19. Pang JC, Chang Q, Chung YF, et al. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol 2005;36:36-43.
20. Teramoto A, Tsukuda K, Yano M, et al. Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers. Oncol Rep 2004;12:141-4.
21. Wong CM, Lee JM, Ching YP, et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003;63:7646-51.
22. Yuan BZ, Jefferson AM, Baldwin KT, et al. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004;23:1405-11.
23. Podar K, Hideshima T, Chauhan D, et al. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets 2005;9:359-81.
24. Qiang YW, Walsh K, Yao L, et al. Wnts induce migration/invasion of myeloma plasma cells. Blood 2005;106:1786-93.
25. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
26. Lin M, van Golen KL. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 2004;84:49-60.
27. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2:941-8.
28. Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147-52.